Ribociclib
ATC L01EF02 · 9 markets · 17 records
AU 4 records · 2 strengths
- 200 mgtabletKISQALI
Records without a stated strength · 1 KISQALI
US 3 records · 1 strengths
- 200 mgtabletKISQALI
ES 3 records · 1 strengths
- 200 mgtabletKISQALI
GB 2 records · 1 strengths
- 200 mgtabletKISQALI
CA 1 records · 1 strengths
- 200 mgtabletKISQALI
TW 1 records · 1 strengths
- 200 mgtabletKISQALI擊癌利200毫克膜衣錠
HK 1 records · 1 strengths
Records without a stated strength · 1 KISQALI
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 KISQALI
| Strength / form / release | US | GB | CA | AU | ES | TW | HK | EU |
|---|---|---|---|---|---|---|---|---|
| 200 mg tablet | KISQALI | KISQALI | KISQALI | KISQALI | KISQALI | KISQALI 擊癌利200毫克膜衣錠 | ||
unknown | KISQALI | KISQALI | KISQALI |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.